Binding affinity of sarpogrelate to 5-HT2A receptor ligand recognition sites in rat renal cortical and mesangial cells in culture

被引:4
|
作者
Nishio, H [1 ]
Yoshikawa, S
Morimoto, Y
Chen, ZQ
Nakata, Y
机构
[1] Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Dept Pharmacol, Hiroshima 7290292, Japan
[2] Hiroshima Univ, Sch Med, Inst Pharmaceut Sci, Dept Pharmacol, Hiroshima 7348551, Japan
来源
GENERAL PHARMACOLOGY | 1999年 / 33卷 / 01期
关键词
5-hydroxytryptamine; 5-HT2A receptors; mesangial cells; ketanserin; sarpogrelate; recognition sites;
D O I
10.1016/S0306-3623(98)00266-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We detected specific binding of H-3-ketanserin (0.6 nM) in rat renal cortical membrane preparations (4.70 +/- 0.57 fmol/mg protein) and mesangial cells (7.55 +/- 0.92 fmole/10(6) cells). Thus, the value in the renal cortical membrane corresponded to 15% of that in the cerebral cortical membranes (30.0 +/- 2.9 fmole/mg protein). The affinity of H-3-ketanserin binding displacement activities by sarpogrelate, a selective 5-HT2A receptor antagonist, in the renal cortical membrane. (IC50; 0.448 +/- 0.061 mu M) and mesangial cells (IC50; 0.656 +/- 0.187 mu M) were almost 100-fold less than that in the cerebral cortical membrane (IC50; 4.62 +/- 1.02 nM). In the renal cortical membranes and mesangial cells, methysergide displaced a tiny fraction of 3H-ketanserin binding at concentrations up to 10 mu M. These results did not explain the functional activity of 5-HT in the mesangial cells, and we conclude that specific H-3-ketanserin binding sites in the mesangial cells consisted of methysergide-resistant and non-serotonergic sites with low affinity for sarpogrelate. (C) 1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:51 / 57
页数:7
相关论文
共 50 条
  • [1] Antinociception in rat by sarpogrelate, a selective 5-HT2A receptor antagonist, is peripheral
    Obata, H
    Saito, S
    Ishizaki, K
    Goto, F
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) : 95 - 102
  • [2] Assessment of Binding Affinity to 5-Hydroxytryptamine 2A (5-HT2A) Receptor and Inverse Agonist Activity of Naftidrofuryl: Comparison With Those of Sarpogrelate
    Aly, Saida Abdel Regal
    Hossain, Murad
    Bhuiyan, Mohiuddin Ahmed
    Nakamura, Takashi
    Nagatomo, Takafumi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 110 (04) : 445 - 450
  • [3] Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling
    Rashid, M
    Manivet, P
    Nishio, H
    Pratuangdejkul, J
    Rajab, M
    Ishiguro, M
    Launay, JM
    Nagatomo, T
    LIFE SCIENCES, 2003, 73 (02) : 193 - 207
  • [4] Cortical 5-HT2A receptor density predicts 5-HT2A receptor mediated behavior in the rabbit
    Dave, KD
    Harvey, JA
    Aloyo, VJ
    FASEB JOURNAL, 2006, 20 (04): : A686 - A686
  • [5] HOMOLOGY MODELING OF THE 5-HT2A RECEPTOR - ORIGIN OF LIGAND-BINDING
    GAO, YD
    LONCHARICH, RJ
    CHANEY, MO
    JOHNSON, MP
    NELSON, DL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 210 : 17 - COMP
  • [6] Different effects of the 5-HT2A receptor agonist DOI and the 5-HT2A receptor antagonist altanserin on D2 receptor binding in the rat brain
    Nikolaus, S.
    Wittsack, H.
    Beu, M.
    Antke, C.
    Hautzel, H.
    Mori, Y.
    Mamlins, E.
    Antoch, G.
    Mueller, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S635 - S635
  • [7] Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor
    Muntasir, Habib Abul
    Bhuiyan, Mohiuddin Ahmed
    Ishiguro, Masaji
    Ozaki, Masanobu
    Nagatomo, Takafumi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 102 (02) : 189 - 195
  • [8] The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands
    Parker, Matthew A.
    Kurrasch, Deborah M.
    Nichols, David E.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (08) : 4661 - 4669
  • [9] Effects of the 5-HT2A receptor antagonist sarpogrelate in diabetic patients with complications -: A pilot study
    Hotta, N
    Nakamura, J
    Sumita, Y
    Yasuda, K
    Ito, M
    Takeuchi, T
    Hara, T
    Sakamoto, N
    CLINICAL DRUG INVESTIGATION, 1999, 18 (03) : 199 - 207
  • [10] Modelling of the 5-HT2A receptor and its ligand complexes
    Lozoya, E
    Loza, MI
    Sanz, F
    MOLECULAR MODELING AND PREDICTION OF BIOACTIVITY, 2000, : 355 - 356